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Abstract
Background: Matrix metalloproteinases (MMPs) are a family of enzymes that are typically released from intracellular
stores to act on specific extracellular substrates. MMP expression and activity can be increased in a neuronal
activity-dependent manner, and further increased in response to tissue injury. MMP substrates include cell adhesion
molecules (CAMs) that are abundantly expressed in the brain and well positioned for membrane proximal cleavage.
Importantly, CAM integrity is important to synaptic structure and axon-myelin interactions, and shed ectodomains
may themselves influence cellular function.
Methods: In the present study, we have examined proteolysis of N-cadherin (N-cdh) by MMP-7, a family member
that has been implicated in disorders including HIV dementia, multiple sclerosis, and major depression. With in vitro
digest assays, we tested N-cdh cleavage by increasing concentrations of recombinant enzyme. We also tested
MMP-7 for its potential to stimulate N-cdh shedding from cultured neural cells. Since select CAM ectodomains may
interact with cell surface receptors that are expressed on microglial cells, we subsequently tested the N-cdh
ectodomain for its ability to stimulate activation of this cell type as determined by nuclear translocation of NF-κB,
Iba-1 expression, and TNF-α release.
Results: We observed that soluble N-cdh increased Iba-1 levels in microglial lysates, and also increased microglial
release of the cytokine TNF-α. Effects were associated with increased NF-κB immunoreactivity in microglial nuclei
and diminished by an inhibitor of the toll-like receptor adaptor protein, MyD88.
Conclusions: Together, these in vitro results suggest that soluble N-cdh may represent a novel effector of
microglial activation, and that disorders with increased MMP levels may stimulate a cycle in which the products of
excess proteolysis further exacerbate microglial-mediated tissue injury. Additional in vivo studies are warranted to
address this issue.
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Background
Matrix metalloproteinase (MMP)-dependent proteolysis is
increasingly recognized as an important effector of physio-
logical plasticity, and learning and memory in particular
[1]. However, since MMP activity can be dramatically up-
regulated with CNS injury, the potential for excessive en-
zyme activity to contribute to tissue injury must be
considered. This latter possibility is supported by numer-
ous in vivo studies in which broad-spectrum MMP inhibi-
tors reduce brain injury in response to ischemia, viral
infection, inflammatory stimuli, genetic disorders such as
fragile X syndrome, and neurotoxicant exposure [2–4].
In terms of the mechanisms by which MMPs influence
tissue injury, many studies have focused on their potential
to influence blood brain barrier (BBB) permeability.
Indeed, MMPs can cleave collagens that are critical
components of the BBB [5–7]. MMPs can also influence
BBB permeability in mouse models of ischemia and in-
flammation [8, 9]. It should be noted; however, that excess
proteolysis of non-BBB targets might also contribute to
MMP-dependent tissue injury.
Transmembrane cell adhesion molecules (CAMs) repre-
sent an important class of MMP substrates [1, 10]. CAMs
are highly expressed on neurons and glial cells, and these
molecules are well positioned to be targeted by MMPs
following enzyme release from intracellular stores. CAM
integrity may be critical to physiological synaptic plasti-
city, axon-myelin interactions, and reactive synaptogenesis
[11–13]. Reduced CAM integrity has been linked to a re-
duction in synapse formation during the regenerative
phase that follows brain injury [13]. In addition, and the
focus of studies pursued herein, CAM fragments may also
represent potent bioactive molecules [10, 14].
MMP-dependent CAM cleavage typically occurs prox-
imal to the transmembrane domain, to release the major
portion of the extracellular domain [15, 16]. The shed
N-terminal fragment (NTF) is often relatively stable, in
that elevated levels of shed NTFs can be detected in
cerebrospinal spinal fluid samples from patients with
CNS injury and/or inflammation [17, 18]. CAM frag-
ments could thus represent a class of damage-associated
molecular patterns (DAMPs) [19, 20].
Receptors for DAMPs include toll-like receptors
(TLRs). These receptors are highly expressed on the
microglia, resident innate immune cells of the brain, and
TLRs are known to engage extracellular matrix protein
fragments that have homology to CAM ectodomain re-
gions. Moreover, the existence of cleavage-generated
TLR ligands is not without precedent. For example, in
Drosophila, extracellular proteolysis generates Spatzle,
which then acts as a ligand for a TLR-analogous immune
and pattern recognition receptor [20–22].
With respect to CNS inflammation and injury, TLR
signaling has been shown to stimulate microglial release
of neurotoxic molecules including the pro-inflammatory
cytokine tumor necrosis factor-α (TNF-α). TLR agonists
have also been linked to inflammasome activation [23, 24].
TLR expression may be increased in the inflamed CNS
[25], and TLR signaling through MyD88 may be critical to
expression of select disease states. It is therefore not
surprising that innate immunity and TLR activation, in
particular, are thought to play an important role in the
murine model of multiple sclerosis, a prototypic inflam-
matory condition [25]. Cells of the innate immune system,
including the microglia, stimulate myelin reactive T cells,
and depletion of macrophages or microglia leads to a
marked attenuation of experimental autoimmune enceph-
alomyelitis (EAE) despite the adequate T cell sensitization
[26, 27]. In addition, recent studies have linked microglial
activation to cortical or hippocampal injury [28, 29].
Microglial activation is also observed in HIV dementia
and is thought to contribute to disease progression [30].
In the present study, we investigate shedding of N-cdh,
a CAM that is relatively abundant in the CNS, using an
in vitro digest system and a cell culture model. In addition,
using a variety of in vitro approaches and primary murine
microglial cell cultures, we investigate soluble N-cdh for




Recombinant mouse N-cdh was purchased from R & D
Systems (Minneapolis, MN; 6626-NC) and reconstituted in
sterile phosphate buffered saline (PBS) prior to use. This
construct contains the soluble ectodomain (Met1-Ala724),
as well as a linker (IEGRMDP) and Glu98-Lys330 of
mouse IgG2A. Recombinant protein used was from a lot
that was tested for endotoxin, which was measured at
0.000648 EU per microgram protein. Recombinant active
MMP-2 and MMP-7 were purchased from EMD Biosci-
ences, Inc. (Billerica, MA), as was the MMP inhibitor GM-
6001. ADAM-10 was purchased from R & D Systems
(Minneapolis, MN) and reconstituted in sterile phosphate
buffered saline (PBS) prior to use. Aliquots were
stored at −80 °C. The RGDS peptide was purchased from
Tocris Bioscience (Bristol, UK; 91037-65-9) and reconsti-
tuted in sterile PBS. Normal mouse IgG was purchased
from Santa Cruz Biotechnology, Inc (Dallas, Tx; sc-2025).
Primary antibodies: to the C-terminal region of the p65
subunit of NF-κB were purchased from Abcam (anti-NF-
κB p65 rabbit polyclonal (ab31481); Cambridge, MA); to
the Iba-1 were purchased from Wako Chemical USA, Inc.
(anti-Iba1 rabbit polyclonal (016-20001); Richmond, VA);
and to the GAPDH were purchased from EMD Millipore
(anti-GAPDH mouse monoclonal IgG1 (MAB374); Biller-
ica, MA). For immunocytochemistry, Alexa Fluor® second-
ary antibodies were purchased from Molecular Probes/
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Thermo Fisher Scientific (Waltham MA). For western blot
analyses, horseradish peroxidase-conjugated secondary
antibodies were purchased from EMD Millipore (goat anti-
mouse-HRP, AP130P) and EMD Millipore (goat anti-
rabbit-HRP, AP132P). The nuclear counterstain, DAPI, was
purchased from Thermo Fisher Scientific (62247). Lyophi-
lized MyD88 inhibitor peptide and its control peptide were
from Imgenex (San Diego, CA) and reconstituted in sterile
PBS to a working concentration of 5 mM. Antibody to N-
cdh was purchased from Millipore (Billerica, MA).
In vitro digests
Unless otherwise noted, in vitro digests were performed as
previously described using 2.5 μg recombinant N-cdh and
0.5 μg recombinant active enzyme [5]. Recombinant hu-
man MMP-2 and MMP-7 were purchased from EMD
Millipore (catalog numbers PF023 and 444270, respectively;
Billerica, MA), while recombinant human ADAM-10 was
purchased from R & D Systems (936-AD; Minneapolis,
MN). The MMP activity inhibitor GM-6001 was purchase
from Tocris (catalog number 2983; Bristol, U.K.) and used
at a final concentration of 2 μM. Reactions were terminated
by addition of denaturing loading buffer and a 95 °C incu-
bation (5 min) followed by freezing. Digestion products
were resolved by electrophoresis on a 4–15% Tris-glycine
polyacrylamide gradient gel and then transferred to a poly-
vinylidene difluoride (PVDF) membrane. The membrane
was subsequently stained with Coomassie Blue.
Cell culture and stimulation
B35 cells
The B35 rat neuroblastoma cell line [31] was obtained
from the American Type Culture Collection (Manassas,
Virginia), and cultures were maintained in DMEM supple-
mented with glucose, penicillin/streptomycin, and 10%
fetal bovine serum at 5% CO2. Cultures were at 75–80%
confluence at treatment. This cell line has been ex-
tensively characterized and used in previous studies
related to neural CAMs (NCAM) [32]. These cells
were treated with vehicle or 500 ng/ml recombinant
MMP-7 for 1 or 6 h as indicated.
Primary microglia
Mice were housed and treated in accordance with the
guidelines of the Georgetown University Animal Care and
Use Committee. Primary murine microglial cells were pre-
pared from C57BL/6 P1-P3 pups as previously described
[33] which results in a cell culture purity >95%. Briefly,
mixed glial cultures were grown for 14–17 days from the
cortices of neonatal murine pups (P1-3) in Microglial
Complete Medium (Minimum Essential Medium Earle’s,
supplemented with 1 mM L-glutamine, 1 mM sodium
pyruvate, 0.6% v/v D-(+)-glucose, 100 μg/mL penicillin/
streptomycin, 4% v/v fetal bovine serum, and 6% v/v horse
serum). After 14–17 days in vitro, the microglia were
isolated via rotary shaking (200 RPM; 37 °C; 5 h) and
subsequently plated at a density of 1 × 105 cells per well
(24-well plates) in 0.5 mL of Microglial Growth Media
(Minimum Essential Medium Earle’s, supplemented with
1 mM sodium pyruvate, 0.6% v/v D-(+)-glucose,
1 mM L-glutamine, 100 μg/mL penicillin/streptomycin,
and 5% v/v fetal bovine serum) and subjected to experi-
mentation as described below 24 h after plating.
Unless otherwise noted, microglial cell cultures were
stimulated with 75 nM recombinant N-cdh in MGM. This
concentration was effective in preliminary dose-response
experiments in which the microglia were exposed to 15,
37.5, or 75 nM recombinant N-cdh, and TNF-α levels in
the conditioned media were measured by ELISA. Using an
ANOVA, differences between the control and stimulated
groups became significant at 75 nM (control 14.75 ± 0.65
S.E.M., 15 nM: 25.75 ± 5.15 S.E.M., 37.5 nM: 103.2 ± 31.5,
and 75 nM: 350.6 ± 130.8); therefore, 75 nM was chosen
for the studies presented herein. For the TNF-α ELISA ex-
periments, microglia were treated with PBS, 75 nM of N-
cdh, heat-inactivated N-cdh (85 °C, 10 min), or normal
mouse IgG (0.4 μg/well) for 24 h and the conditioned
media retained and assayed as described below. Microglia
used for the integrin blocking experiments were pre-
treated for 30 min in the presence or absence of 500 μM
RGDS followed by exposure to N-cdh or PBS for 24 h.
TNF-α release was quantified in the conditioned media.
Lysates and Western blot
Lysates from cultured cells were prepared via the addition
of lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% so-
dium deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride
(PMSF), and 1× protease inhibitor cocktail (Sigma P8340)].
The mixture was placed into a microfuge tube, sonicated
for 10 s, kept on ice for 20 min, and then spun at
14,000 rpm for 15 min at 4 °C in a microcentrifuge.
Supernatants were then saved and used in Western blot
experiments. Western blot was performed using 40 μg of
protein per lane for B35 cell lysates or 12 μg per lane for
primary microglial cell lysates. Prior to analysis, samples
were mixed with sample buffer containing 5% β-
mercaptoethanol and boiled for 5 min at 95 °C. Electro-
phoresis was performed on Tris-glycine polyacrylamide
gradient gels (Biorad, Hercules, CA). Following electro-
phoretic transfer of the protein to nitrocellulose or PVDF
(Iba-1 experiments), membranes were stained with
Ponceau S to ensure equal loading and transfer. Mem-
branes were then blocked in 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween (TBST) for 1 h. The blot
was then probed with the indicated primary antibody, at a
dilution recommended by the manufacturer (see figure le-
gend for specific dilutions), overnight at 4 °C. After
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washing the membrane three times (15 min each) in TBST,
antigen-antibody complexes were incubated with the ap-
propriate HRP-conjugated secondary antibody for 1–2 h at
room temperature. The membrane was then washed again
in TBST, followed by TBS and immunoreactive bands were
visualized using electrochemiluminescence (Amersham/
GE Healthcare Life Science; Piscataway, NJ).
ELISA
TNF-α, pro-matrix metalloproteinase-9 (MMP-9),
interleukin-6 (IL-6), and monocyte chemoattractant
protein-1 (MCP-1) protein concentrations in cell culture
supernatants were quantified using commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s instructions (R&D Sys-
tems; Minneapolis, MN).
Immunocytochemistry (NF-κB)
Microglia were plated on glass coverslips (1 × 105 cells/
coverslip; 12 mm; Deckglaser, Germany), stimulated as de-
scribed, and subsequently processed for immunocyto-
chemistry. More specifically, following treatment, cells
were washed with PBS for 5 min, fixed with PBS contain-
ing 4% (w/v) paraformaldehyde and 4% (w/v) sucrose
(pH 7.4) at room temperature for 15 min, permeabilized
in PBS containing 0.1% (v/v) triton X-100 for 5 min, and
blocked for 1 h with PBS containing 10% (v/v) goat serum.
Cells were subsequently incubated overnight at 4 °C with
rabbit anti-NF-κB (p65; 1:1000, Abcam; Cambridge, MA)
in blocking buffer. This antibody was generated against
amino acids 532-551 of the p65 subunit. Antibody/antigen
complexes were visualized following incubation with
Alexa Fluor® 594 conjugated goat anti-rabbit IgG second-
ary antibody (1:1000; Molecular Probes/Thermo Fisher
Scientific; Waltham MA) in PBS containing 0.1% (v/v) tri-
ton X-100 and 1% goat serum. Unbound 2° antibody was
removed by washing with PBS containing 0.1% (v/v) triton
X-100. Cells were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI; 13.0 ng/μL; Thermo Fisher Scientific)
in PBS for 5 min followed by two washes with PBS. Cover-
slips were mounted with Citifluor (Ted Pella, Redding,
CA) and sealed with nail polish. Cells were imaged using a
Zeiss Axioskop fluorescent microscope (Carl Zeiss;
Thornwood, NY). For nuclear signal quantification,
images of NF-κB and DAPI were captured from five
distinct, randomly selected regions of each treatment con-
dition for 25–60 cells per treatment group. Quantification
of nuclear NF-κB intensity was completed as previously
described [34, 35] utilizing Image J software (National
Institutes of Health; Bethesda, MD).
MyD88 homodimerization inhibition
Primary microglia were plated as described above (1 ×
105 cells/coverslip). Cells were subsequently pre-treated
with 200 μM of control peptide or MyD88 inhibitory pep-
tide (Imgenex; San Diego, CA) for 30 min, followed by ex-
posure to 75 nM recombinant N-cdh for 2 h. Cells were
subsequently processed for immunocytochemistry as de-
scribed above, and supernatants collected for ELISA.
Statistical analysis
Data were analyzed with Graphpad Prism software using a
two-tailed t test or ANOVA for comparisons of more than
two groups. Significance was determined as p < 0.05.
Results
Cleavage of N-cdh by MMP-7
In previous work, we have observed increased levels of
MMP-7 in association with HIV dementia [36]. MMP-7
has also been linked to neuroinflammation with multiple
sclerosis and depression [37–39]. Moreover, MMP-7 in-
hibitors have been shown to reduce N-cdh shedding
from vascular smooth muscle cells [40]. Initial experi-
ments were therefore performed to examine cleavage of
recombinant N-cdh with increasing concentrations of
MMP-7. Results are shown in Fig. 1a and suggest that
MMP-7 generates discreet cleavage fragments. Though
the identity of precise cleavage sites cannot be inferred
without sequence analysis, the presence of discreet high
molecular weight bands is consistent with proteolytic
cleavage that generates long portions of the ectodomain.
The band at approximately 90 kDa is consistent with the
described propensity for MMPs to cleave CAMs at
membrane proximal sites while smaller bands are con-
sistent with additional cleavage sites within the full N
terminal domain [1, 15]. Shown in Fig. 1b, c are results
from in vitro digests using MMP-2 and ADAM-10,
respectively. The latter is known to stimulate ectodomain
shedding of N-cdh [41] and, similar to MMP-7, it gener-
ates cleavage fragments of approximately 90 kDa (arrow).
In contrast, in our experimental system, MMP-2 did not
generate cleavage fragments. Shown in Fig. 1d are results
from digests performed using 1.25 μg rN-cdh and 0.5 μg
rMMP-7 in the presence or absence of 2 μM GM-6001,
an inhibitor of MMP activity. As can be appreciated, GM-
6001 inhibited MMP-7-associated cleavage of recombin-
ant N-cdh. An equivalent amount of DMSO (3.8%), in
which GM-6001 was dissolved, did not inhibit MMP-7-
mediated cleavage (rN-cdh + DMSO+MMP-7).
To investigate potential MMP-mediated cleavage of
membrane-tethered N-cdh and shedding from neuronal
cells in particular, subsequent studies tested MMP-7 for
its ability to stimulate N-cdh shedding from a neuronal
cell line [31]. We used 500 ng/ml MMP-7 as MMP
levels in the nanogram per milliliter range have been de-
tected in cerebrospinal fluid samples of patients with
HIV dementia. As shown in Fig. 1e, treatment of B35
neuronal cells with MMP-7 was associated with a rapid
Conant et al. Journal of Neuroinflammation  (2017) 14:56 Page 4 of 12
reduction in detectable full length N-cdh immunoreac-
tivity in cell lysates, consistent with release of ectodo-
main into the culture supernatant.
Soluble N-cdh acts on primary microglial cells to stimulate
nuclear translocation of NF-κB and increased levels of Iba-1
in lysates
Ectodomain shedding of CAMs would be expected to alter
trans-cellular adhesive interactions [42]. In addition, a sub-
set of CAM C-terminal fragments (CTFs) can influence
gene transcription [16, 43]. A non-mutually exclusive
mechanism by which CAM shedding could substantially
influence cell biology involves the potential for soluble
CAMs to interact with previously unengaged cell sur-
face receptors to stimulate intracellular signaling cas-
cades [10, 14, 44, 45].
Microglial cells express relatively high levels of potential
receptors for adhesion molecule fragments, including integ-
rins and TLRs. Moreover, activation of this cell type has
been increasingly implicated in the pathogenesis of
neurodegenerative disorders including MS [29]. We there-
fore tested soluble N-cdh ectodomain for its ability to
stimulate microglial activation as measured by increased
nuclear translocation of NF-κB and expression of ionized
calcium-binding adapter molecule, Iba-1, protein. As
shown, soluble N-cdh stimulates a qualitative and
quantitative increase in nuclear NF-κB immunoreac-
tivity (Fig. 2a, b), as inferred by immunostaining for
the p65 subunit and analysis of signal intensity. In
addition, N-cdh stimulates an increase in Iba-1 levels in
microglial lysates (Fig. 2c, d). As determined by densito-
metric analysis, the N-cdh stimulated increase in Iba-1 to
GAPDH signal intensity is significant at p < 0.05.
Soluble N-cdh increases release of microglial proteins
including TNF-α
Though microglial cells are heterogeneous in terms of
their phenotype, recent studies suggest that populations
may be relatively polarized with “classically activated”
populations described as M1 cells and alternatively or
Fig. 1 Cleavage of N-cdh by MMP-7. In (a) recombinant N-cdh (2.5 μg) was incubated with or without MMP-7 for 2 h at 37 °C. Digestion products
were resolved by polyacrylamide gel electrophoresis, transferred to nitrocellulose, and then stained with Coomassie Blue (a). MMP-7 was used at
increasing concentrations of 0.5, 1, and 1.5 μg/ml. In (b and c), a similar experiment was performed with MMP-2 or ADAM-10, respectively. While
we do not observe appreciable cleavage with MMP-2 (b), as indicated by the arrow (c), ADAM-10 generated cleavage fragments of approximately
90 kDa. MMP-2 and ADAM-10 digests were run on the same gel for lanes shown in each figure but separated from other lanes for clarity. In (d),
we demonstrate that the hydroxamate MMP inhibitor GM-6001 (GM) prevents MMP-mediated N-cdh cleavage, as expected, and that DMSO, in
which GM is solubilized, does not impair generation of cleavage fragments including that observed at approximately 90 kDa (arrow). In (e), the
integrity of N-cdh was also examined by Western blot using lysates from simultaneously prepared control and MMP-7-treated B35 cell culture
wells. As indicated, time points at 1 and 6 h following treatment were examined in treated or control culture lysates. A reduction in full-length
protein is observed within 1 h of MMP-7 treatment
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de-activated populations described as M2 [46]. Increased
release of the pro-inflammatory cytokine TNF-α can fol-
low from NF-κB signaling and is typically associated
with M1 polarization, which in turn may be particularly
inimical in the setting of neurodegeneration and neuro-
inflammation [47]. As shown in Fig. 3a, b, release of
TNF-α is significantly increased in N-cdh-stimulated
microglia. In contrast, equivalent concentrations of heat-
inactivated N-cdh or IgG control or PBS treatment did
not have a significant effect on TNF-α release (Fig. 3a, b).
Due to limitations associated with increased release of a
single soluble activation marker, additional experiments
were performed to assess N-cdh-dependent release of
MMP-9 and MCP-1. Results are shown in Fig. 3c, d and
demonstrate that N-cdh can more generally enhance re-
lease of potential inflammatory mediators.
Pre-treatment of microglial cells with an integrin antagonist
does not abrogate N-cdh-stimulated TNF-α release
Similar to their full-length counterparts, shed CAMs can
interact with cell surface receptors through homophilic
and heterophilic interactions. In previous studies, we
and others have observed that shed CAMs can bind to
unengaged integrins to in turn stimulate changes in
intracellular signaling [14, 44, 48].
Microglia express a variety of integrins including α5β1,
an integrin that has been linked to both microglial acti-
vation and increased expression of the pro-inflammatory
Fig. 2 Soluble N-cdh acts on primary microglial cells to stimulate nuclear translocation of NF-κB and increased levels of Iba-1 in lysates. Microglia
were immunofluorescently labeled for the p65 subunit of NF-κB (rabbit polyclonal anti-p65, 1:1000; Alexa Fluor 594-conjugated goat anti-rabbit
IgG secondary antibody, 1:1000) and counterstained with DAPI, following a 2-h exposure to either vehicle (PBS) or 75 nM of soluble N-cdh. In
comparison to control conditions, incubation of microglia with soluble N-cdh induced a robust increase in nuclear NF-κB p65 immunoreactivity,
consistent with classical microglial activation. Representative images are shown in (a) and quantification in (b) (p < 0.01). The scale bar in (a)
(white) represents 20 μm. Western blot analysis (c) shows that Iba-1 protein levels were also increased in microglial lysates (12 μg protein/lane;
anti-Iba1 rabbit polyclonal, 1/1000; HRP-goat anti-rabbit IgG, 1/3000) following an 18-h exposure of microglia to 75 nM of N-cdh. Membranes
were subsequently reprobed for GAPDH as a loading control (anti-GAPDH mouse monoclonal IgG1, 1/20,000; HRP-goat anti-mouse IgG, 1/2000).
Data in (d) show results of densitometric analysis comparing changes in Iba-1 signal relative to GAPDH in control or N-cdh-stimulated cell lysates.
The difference between the control and N-cdh-stimulated Iba-1/GAPDH density ratio is significant at p < 0.05. Arrows indicate increased nuclear
NF-κB immunoreactivity
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molecule MMP-9 [49]. This is one of several integrins that
recognizes ligands with an RGD amino acid sequence
[50]. We therefore tested an RGDS peptide, which blocks
the activation of RGD-binding integrins, for its potential
to abrogate N-cdh-stimulated TNF-α release. The micro-
glia were pretreated for 30 min in the presence or absence
of 500 μM RGDS followed by exposure to N-cdh or PBS
for 24 h. TNF-α release was quantified in the conditioned
media. Results, shown in Fig. 4, demonstrate that this pep-
tide does not abrogate N-cdh-stimulated TNF-α release in
our experimental system.
A peptide inhibitor of MyD88-dependent TLR signaling,
abrogates N-cdh-stimulated NF-κB translocation and
TNF-α release
TLRs represent a class of pattern recognition receptors
(PRRs) that are highly expressed on microglia and linked
to classical activation. PRRs are activated by varied
exogenous ligands called pathogen-associated molecular
patterns (PAMPs) which include triacyl lipopeptides,
flagellin, dsDNA, ssRNA, and bacterial lipopolysaccha-
rides [51]. More recently, these same TLRs have been
shown to bind endogenous ligands, referred to as
damage-associated molecular patterns (DAMPs), mole-
cules that are typically exposed or increased with tissue
injury [19, 20, 25, 52]. Since soluble CAM levels are
A B
C D
Fig. 3 Soluble N-cdh increases microglial cell release of immune modulators including TNF-α. Supernatants from control or N-cdh-stimulated
(75 nM, 18 h) microglia were tested by ELISA for TNF-α. Results from an experiment performed in triplicate with vehicle, N-cdh, or an equivalent
amount of heat-inactivated protein (HI N-cdh; 95 °C for 30 min) are shown in (a) while results from a quadruplicate experiment with vehicle and
IgG controls are shown in (b). The difference between control and N-cdh is significant at *p < 0.05 for both experiments. The difference between
control groups is not significant for either. N.D. = not detectable. In (c and d), we show results from a similar experiment performed in triplicate
with vehicle or N-cdh (75 nM, 18 h). In this experiment, supernatant levels of pro-MMP-9 or MCP-1 were evaluated as indicated, and a significant
increase in both was observed
Fig. 4 Pre-treatment of microglial cells with an integrin antagonist
does not abrogate N-cdh-stimulated TNF-α release. An RGDS peptide
was tested for its potential to attenuate N-cdh-stimulated TNF-α
release from primary microglial cells. Supernatants from vehicle control
(PBS), RGDS pre-treated (500 μM, 30 min pretreatment), and N-cdh
(75 nM) with or without RGDS pre-treatment (500 μM, 30 min
pretreatment) were collected 18 h later and analyzed by ELISA. The
mean and standard error are shown in Fig. 4, and difference between
pre-treated and non pre-treated N-cdh groups was not significant
(N.S.). Supernatant from both groups that received N-cdh had
significantly higher levels of TNF-α compared to control and RGDS
alone (n = 4 per group; *p < 0.05)
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increased with tissue injury [53–55], and have regions
homologous to matrix fragments that have been impli-
cated in TLR signaling [20], CAM fragments could repre-
sent a class of DAMPs. We therefore examined a peptide
inhibitor of MyD88 homodimerization, an event necessary
for signaling through a subset of TLRs, for its potential to
abrogate N-cdh-stimulated NF-κB translocation and
TNF-α release. Because NF-κB translocation occurs rela-
tively quickly, in these experiments, we examined changes
in both NF-κB and TNF-α at 2 h, a timepoint that we
previously demonstrated to be appropriate for both p65
nuclear translocation and TNF-α release [56]. As shown
in Fig. 5, inhibition of MyD88 homodimerization reduced
N-cdh-stimulated increases in both endpoint measures.
These data suggest that TLR signaling may contribute to
N-cdh-mediated microglial activation.
Discussion
MMPs represent a family of enzymes initially named for
their potential to remodel extracellular matrix [57, 58].
Expression and/or release of select MMPs is increased in
the background of neuroinflammation [59]. Published
studies have demonstrated that MMP activity can cleave
BBB tight junction and basement membrane components
to facilitate the CNS ingress of specific leukocyte subpop-
ulations [7]. Recently published work posits that MMPs
can produce DAMPs through their potential to process
large ECM proteins such as hyaluron [60, 61]. Less well
studied is the question of whether increased MMP activity
contributes to disease pathogenesis through excessive
CAM cleavage.
CAMs represent an important target for cell-associated
and cell-secreted MMPs. In vitro and in vivo studies sug-
gest that metalloproteinase activity is concentrated at the
cell surface [62, 63] and emerging evidence links CAM
shedding to important physiological and pathological end-
points [48, 64]. CAM integrity is important to synaptic
stability, axon-myelin interactions, and reactive synapto-
genesis following injury [13, 42]. In addition, shedding of
specific CAMs is linked to the generation of intracellular
domains that influence gene transcription [43]. For ex-
ample, N-cdh shedding leads to the generation of a CTF
that inhibits CREB-dependent gene transcription [16]. A
third and non-mutually exclusive consequence of CAM
shedding, and one that is increasingly appreciated in
recent studies, is the possibility that shed NTFs are
themselves potent effectors of diverse normal and patho-
logical processes. These fragments are relatively stable, as
Fig. 5 Inhibition of MyD88-dependent TLR signaling abrogates N-cdh-stimulated TNF-α release and NF-κB translocation. Microglia were pre-treated
with either 200 μM of control peptide (CTLpep) or inhibitory MyD88 peptide (MyD88pep) for 30 min, followed by a 2-h exposure to 75 nM soluble
N-cdh (a–c). Supernatants were collected and fixed cells were immunostained for NF-κB (rabbit polyclonal anti-p65, 1:1000; Alexa Fluor 594-conjugated
goat anti-rabbit IgG secondary antibody, 1:1000) and counterstained with DAPI, while cell culture supernatants were subsequently analyzed for TNF-α
protein concentration via ELISA (c). Data shown is representative and from one of two separate experiments each performed in triplicate. As shown,
MyD88 inhibition led to a reduction in N-cdh-stimulated NF-κB translocation. Representative immunostaining is shown in (a) and quantification of
nuclear signal intensity change is shown in (b) (n = 60 control and 84 MyD88 inhibitor-treated cells). The difference between nuclear signal intensity in
vehicle and N-cdh is significant at *p < 0.05. The scale bar again represents 20 μm. In addition, as shown in (c), inhibition of MyD88 homodimerization
resulted in a significant decrease in N-cdh-stimulated TNF-α release from microglia in comparison to control conditions (*p < 0.05). Arrows in CTLpep
indicate nuclear NF-κB, which is diminished with the inhibitory MyD88 peptide
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suggested by studies in which varied CAM NTFs can be
detected in cerebrospinal fluid samples from normal and/
or diseased individuals [53–55, 65]. Similar to their full-
length counterparts, shed CAMs can likely interact with
cell surface receptors through homophilic and heterophi-
lic interactions [14, 66]. This is supported by published
work in which soluble ICAM-5 can interact with neuronal
surface molecules including full-length ICAM-5 and β1
integrins [14, 15].
TLRs represent another class of cell surface molecules
that might be engaged by soluble CAMs as these PRRs
are activated by injury-associated molecular patterns
(DAMPs) [19, 20, 25, 52]. Soluble CAM levels may be
increased with brain injury [53–55], and these molecules
have regions homologous to matrix components that
have been implicated in TLR signaling [20]. CAM frag-
ments could therefore represent a class of DAMPs.
In the present study, we show that MMP-7 can cleave
recombinant N-cdh. Similar to ADAM-10, which has
been demonstrated to stimulate ectodomain shedding of
N-cdh [41, 67, 68], MMP-7 generates a fragment of ap-
proximately 90 kDa. Though sequencing studies would
be confirmatory, given that recombinant N-cdh contains
the entire ectodomain and is of similar molecular weight
to native protein, this result is consistent with the de-
scribed ability of MMPs to cleave CAMs at a membrane
proximal position. Ectodomain shedding is further sup-
ported by loss of N-terminal N-cdh immunoreactivity in
lysates from MMP-7-treated neural cells. While our
focus was on MMP-7, due to overlapping substrate spe-
cificity, we acknowledge that additional MMPs might
stimulate N-cdh shedding in select settings. A subset of
family members is expressed in the brain and, like
MMP-7, may be upregulated with inflammation [69].
Herein, we also show that soluble N-cdh can stimulate
microglial activation as demonstrated by varied end-
points including increased expression of Iba1, nuclear
localization of NF-κB, and release of TNF-α. Moreover,
we suggest that TLR signaling in particular can contrib-
ute to N-cdh-stimulated microglial activation, since end-
point measures are significantly reduced by an inhibitor
of MyD88 signaling. Though inhibition is incomplete, it
should be noted that blocking MyD88 signaling with
peptides or siRNA typically has partial effects in terms
of attenuating TLR signaling [52, 70, 71]. Changes in
overall TNF-α levels are of interest, as is increased nu-
clear localization of a transcription factor linked to indu-
cible TNF-α expression. Importantly, however, while
both likely reflect microglial activation, the two are not
necessarily causally related. Transcription factors add-
itional to NF-κB are important to TNF-α. Moreover,
TNF-α can be released from preformed stores [72].
Of additional note, N-cdh also increased expression
and/or release of additional proteins that may be
regulated in an NF-κB-dependent manner: MCP-1
and MMP-9 [73, 74].
Soluble N-cdh-dependent microglial activation is of
interest. Classical microglial activation has been impli-
cated as a mediator of hippocampal and synaptic injury
in varied disease models. A recent study, which focused
on hippocampal dysfunction in a mouse model of mul-
tiple sclerosis, noted that a loss of inhibitory interneu-
rons occurred with associated microglial activation and a
relative lack of infiltrating blood-borne immune cells
[29]. Recent work has also shown that MMP-7 is in-
creased with major depression [75], a condition that is
increasingly associated with microglial activation [76].
That N-cdh stimulated an increase in TNF-α release is
of interest in that this cytokine is typically associated
with classical or pro-inflammatory M1 polarization.
Though M1 as opposed to immunoregulatory or anti-
inflammatory M2 polarity is a complex distinction, and
characteristics of each are not mutually exclusive, it is
worth noting that the M1 phenotype may be inimical to
neuronal repair [47].
The potential for an MMP-generated fragment to acti-
vate microglia also provides a potential mechanistic link
for studies that have shown reduced microglial activation
in the background of MMP inhibition. For example,
tetracycline and tetracycline derivatives can directly in-
hibit the activity of already formed MMPs via chelation
of the active site zinc atom [77]. Tetracycline derivatives
are now used in varied disease models to reduce micro-
glial activation. It is thus tempting to speculate that re-
duced microglial activation follows, at least in part, from
reduced levels of microglial-activating CAM fragments.
Herein, we also show that specific cell surface receptors
may be important to soluble N-cdh-dependent microglial
activation. As compared to other resident cells of the
CNS, microglia express high levels of two receptor classes
that have been linked to their activation, integrins and
TLRs [78, 79]. Our studies suggest a role for the latter in
N-cdh-dependent effects. We cannot, however, rule out
an effect for other cell surface molecules including CAM-
binding fibroblast growth factor (FGF) receptors [80]. In
addition, though an antagonist for RGD-binding integrins
did not block N-cdh-stimulated TNF-α release in our sys-
tem, it would be premature to exclude a role for integrins
in MMP-dependent microglial activation. For example, N-
cdh could interact with non-RGD-binding integrins that
are linked to microglial activation. Moreover, damage-
associated MMPs might stimulate shedding of additional
CAMs, such as ICAM-5, whose NTFs might engage RGD
and non-RGD-binding microglial integrins [78, 81].
While pathological shedding of CAMs may stimulate
widespread and injurious microglial activation, it is im-
portant to consider that regulated shedding might be
important to physiological microglial functions. For
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example, since MMPs can be released in a neuronal activity
dependent manner, it is tempting to speculate that regu-
lated CAM-dependent microglial activation could poten-
tially contribute to physiological synaptic pruning [82].
Conclusions
In summary, our data suggest that N-cdh shedding can be
stimulated by MMP-7 and that soluble N-cdh represents a
novel effector of classical microglial activation. Future
in vivo studies to better understand the consequences of
disease-associated CAM shedding are warranted.
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